Four University of Chicago scientists receive $8 million in innovation awards from National Institutes of Health
September 18, 2007
The National Institutes of Health is awarding separate research awards to four young University of Chicago scientists totaling $8 million to conduct promising but unconventional research that could lead to new medical treatments and a better understanding of the factors that contribute to problem adolescent behavior. The NIH grants are part of a $100 million investment in the future of science to 39 innovative researchers nationwide.
Margaret Gardel, 30, PhD, Assistant Professor in Physics, and Rustem Ismagilov, 34, PhD, Associate Professor in Chemistry, will each receive $2.5 million to conduct biological research over the next five years as NIH Director's Pioneer Award recipients. Gardel and Ismagilov are among 12 recipients of 2007 Director's Pioneer Awards, which are designed to support individual scientists of exceptional creativity who propose pioneering approaches to major challenges in biomedical or behavioral research.
Receiving NIH New Innovator Awards, meanwhile, will be Kristen Jacobson, 39, PhD, Assistant Professor of Psychiatry, and Dorothy Sipkins, 38, MD, PhD, Assistant Professor of Medicine. Jacobson and Sipkins are among the first group of NIH Director's New Innovator Award recipients. The 27 New Innovator Awards will each provide $1.5 million to stimulate highly innovative research by promising new investigators.
"It's gratifying to see four of these prestigious research awards, about 10 percent of the total, coming to this University," said James Madara, MD, Dean of the Biological Sciences Division and the Pritzker School of Medicine, Vice President for Medical Affairs and Chief Executive Officer of the Medical Center at the University of Chicago. "It is particularly rewarding to have NIH recognize not just our innovators in the biological sciences but to recognize the important and growing contribution to the understanding of medicine that is coming from the physical sciences as well, exactly the sort of interactions we have long been know for and continue to nurture."
"The research pursued by Professors Gardel and Ismagilov is very much representative of the marriage that exists between the biological and the physical sciences today," said Robert Fefferman, Dean of the Physical Sciences Division at the University of Chicago. "Both of these brilliant young scientists are affiliated with the University's Institute for Biophysical Dynamics. They, along with their like-minded colleagues in the Institute, have devoted themselves to solving difficult issues that today so often cross over the disappearing boundaries between the biological and the physical sciences. The NIH Director's Pioneer Awards will be a real boon to their efforts."
In her project, Gardel will investigate how living, biological matter differs from inert, physical matter. Her work could ultimately provide biomedical scientists with the means to devise new therapies for the treatment of cancer and other diseases.
Gardel specializes in soft condensed matter physics—the rules governing the deformation of soft materials such as biological tissue, mayonnaise and soot. She received her PhD in physics from Harvard University in 2004, then completed a postdoctoral fellowship in physics at the Massachusetts Institute of Technology. A second postdoctoral fellowship, in cell biology, followed at the Scripps Research Institute in California.
Gardel joined the Chicago faculty this summer. She maintains office and laboratory space in the Gordon Center for Integrative Science, which houses physicists, chemists, biologists and medical researchers in close proximity. She will draw upon this varied background and the expertise of her Chicago colleagues to develop new ways to study the cytoskeleton, the dynamic scaffolding of the cell. "The cellular cytoskeleton is, inarguably, the most bizarre, complex, and exciting material that we have ever confronted," Gardel said.
The major components of inanimate matter, such as a car, typically remain essentially unchanged from day to day. Not so a cell, which maintains shape via rods of filamentous proteins called "actins." "The cell basically assembles and disassembles its clutch, its engine, its wheels, its whole structure. We want to understand how those materials in the cell are assembling and disassembling," Gardel explained.
Motor proteins must interact with one another and the cytoskeleton in order to generate the forces needed for a cell to change its shape. "Shape changes occur during cell division, when a mother cell divides into two daughter cells during embryo development. And it's misregulated in cancers and tumor formation and also in cell migration," she said.
Ismagilov joined the Chicago faculty in 2001. He specializes in microfluidic technology—the flow of fluids through channels thinner than a human hair—to understand and control complex chemical and biological systems at critical times and locations. With his Pioneer Award, Ismagilov will develop droplet-based microfluidic technologies for quantitative studies of protein aggregation diseases and aging at the molecular level and in entire organisms.
"Understanding and controlling protein aggregation are major challenges for biomedical research and in developing protein-based pharmaceuticals," Ismagilov said. "Protein misfolding and aggregation are associated with a number of human diseases, including Alzheimer's, Parkinson's and Huntington's diseases, as well as type 2 diabetes, and are undeniably linked to aging processes that affect both the quality and duration of human life."
Current studies of protein aggregation and disease come with a high price tag in labor and time. Tiny test samples and the inability to experimentally reproduce aggregation events create further problems, but microfluidics addresses all of these issues.
For studies at the molecular level, Ismagilov will develop microfluidic systems capable of rapidly generating, manipulating and assaying protein aggregates of various sizes, shapes and compositions. In parallel studies at a broader level, he will develop microfluidic technology to precisely induce and monitor protein aggregation in living cells and organisms over time. These techniques will allow him to observe the initiation and progression of protein aggregation diseases.
In addition to his Pioneer Award, Ismagilov also has been named the recipient of the 2008 Award in Pure Chemistry from the American Chemical Society (ACS). The award goes to scientists no older than 35 in North America who have accomplished research of unusual merit for an individual on the threshold of his or her career. Ismagilov will receive the award next April at the ACS national meeting in New Orleans.
Jacobson will study the effects of individuals, family, peers and neighborhood on adolescent problem behavior—particularly looking at how those factors relate to the variations in problem behavior from one adolescent to the next.
A Chicago faculty member since 2005, Jacobson has a broad, multidisciplinary background. Her PhD from Pennsylvania State University focused on behavioral genetics. Her postdoctoral work at the Virginia Institute for Psychiatric and Behavioral Genetics was devoted to understanding the complex role of genes and environments on individual differences in problem behavior.
Phase One of Jacobson's study consists of an in-school assessment of approximately 7,000 6th to 8th graders in 10 socioeconomically and racially and ethnically diverse schools in the Chicago Public School system. The assessment will obtain data on environmental and psychosocial factors that may account for socioeconomic, racial and ethnic differences in problem behavior.
Next, 800 of those 7,000 students will be studied—pairs of siblings, half siblings, and unrelated siblings. They and their caregivers will be brought to the University of Chicago for neuroscience and behavioral assessments to identify environmental, biological and psychosocial variables that account for individual differences in problem behavior, and to further determine whether these effects are genetically or environmentally caused.
The final phase takes 200 of those 800 students and studies 60 sibling pairs where the problem behavior is similar, and 40 pairs where the problem behavior is dissimilar. Each student will be given a magnetic resonance imaging test. In addition, a small pilot study of 20 sibling pairs with extremely dissimilar problem behavior will investigate whether environments alter gene expression.
"This nested design uses a bioecological framework to measure risk and protective factors at multiple levels of analysis—'from neighborhoods to neurons and beyond,'" Jacobson said.
In her project, Sipkins will investigate molecular characteristics of tissue microenvironments, or "niches," within the bone marrow and how normal, healthy hematopoietic stem cells, which give rise to the many kinds of blood cells, compete with malignant cells to occupy these coveted niches.
A medical oncologist who specializes in leukemia, Sipkins came to the University of Chicago in 2005 on a fellowship at the Dana-Farber Cancer Institute in Boston. In 2006, she was one of the first 10 grant recipients selected by the newly created Illinois Regenerative Medicine Institute, one of only four state programs that at the time could commit public funds to stem cell research.
The Innovator Award will enable Sipkins to continue to combine state-of-the-art imaging techniques, performed on living mice, with cell and molecular biology approaches to learn more about these stem cell niches. She will study how normal, healthy bone marrow stem cells find a niche and how niche environment regulates stem cell functions such as self-renewal and differentiation.
Sipkins also will focus on the role of the niche in leukemia. Malignant cells often invade these niches, crowding out the normal tenants. Her team has already identified the molecular signals that attract leukemic cells to a niche, allow them to gain entry and eventually take over.
Her goal is to define the molecular architecture and functional significance of a niche, determine how tumor growth impacts the niche, learn how benign and malignant cells compete within a niche, and use this knowledge to design precisely targeted anti-cancer treatments that spare normal bone marrow and improve the efficacy of stem cell-based therapies.
"Given the importance of stem cell-based transplantation therapies as well as the clinical significance of tumor metastastis to the bone marrow, there is great therapeutic potential in understanding these cellular interactions," Sipkins said.
The University of Chicago Medicine
950 E. 61st Street, Third Floor
Chicago, IL 60637
Phone (773) 702-0025 Fax (773) 702-3171